Clinical Trial Update: Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and immunogenicity of the Chikungunya vaccine VRC-CHKVLP059-00-VP in healthy adults has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chikungunya Virus Infection

Drugs mentioned

• VRC-CHKVLP059-00-VP

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Chikungunya Virus Infection | Phase 2 | Status: COMPLETED | Results posted: 2019-05-14